Evidence map›Paper›PMID 31312750›Full record

ArticleAmerican journal of ophthalmology case reports2019

High fluence PACK-CXL as adjuvant treatment for advanced Acanthamoeba keratitis.

Mehrdad Nateghi Pettersson, Neil Lagali, Jes Mortensen, Victor Jofré, Per Fagerholm

Open access · goldAbstract readCase Reports
In one paragraph

Article in American journal of ophthalmology case reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. New Frontiers inBiology · 2023
    Review
  6. Article
  7. Article
  8. Review
  9. Challenges in Acanthamoeba Keratitis: A Review.Journal of clinical medicine · 2021
    Review
  10. Taiwan journal of ophthalmology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Mehrdad Nateghi PetterssonDepartment of Ophthalmology, Ryhov County Hospital, 553 05, Jönköping, Sweden.
Neil LagaliDepartment of Ophthalmology, Institute for Clinical and Experimental Medicine, Faculty of Medicine, Linköping University, 581 83, Linköping, Sweden.
Jes MortensenDepartment of Ophthalmology, Ryhov County Hospital, 553 05, Jönköping, Sweden.
Victor JofréDepartment of Ophthalmology, Ryhov County Hospital, 553 05, Jönköping, Sweden.
Per FagerholmDepartment of Ophthalmology, Institute for Clinical and Experimental Medicine, Faculty of Medicine, Linköping University, 581 83, Linköping, Sweden.
Ryhov Hospital Jönköping · SELinköping University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo describe the outcome of adjuvant high fluence photoactivated chromophore for infectious keratitis cross-linking (PACK-CXL) used to treat an advanced form of refractory Acanthamoeba keratitis (AK) diagnosed several months after initial presentation. OBSERVATIONS: An otherwise healthy 24-year old female presented with a severe unilateral keratitis. The diagnosis eluded clinicians for several months and when finally confirmed as AK, anti-amoebic therapy was instated and only appeared to be effective after addition of high fluence PACK-CXL. CONCLUSION AND IMPORTANCE: In this case of advanced AK, high fluence PACK-CXL treatment given adjuvant to pharmacologic anti-amoebic therapy resulted in lasting pain relief, re-epithelization and eradication of the Acanthamoeba parasite. Given adjuvant to anti-amoebic pharmacotherapy, high fluence PACK-CXL might be a useful method for treating typically refractory advanced AK.

Indexed as

Acanthamoeba keratitisPhototherapy

Identifiers

PMID31312750
PMCPMC6609835
OpenAlexW2951194454

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.